v3.26.1
Schedule of Segment Financial Performance (Details) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Total assets $ 519,146,435 $ 3,721,624
Loss from operations (20,106,066) (12,433,792)
Unrealized loss on digital assets holdings (22,010,362)
Consolidated total loss before income taxes (42,103,363) (12,197,568)
Digital Asset Treasury [Member]    
Segment Reporting Information [Line Items]    
Total assets 513,964,900
Loss from operations (2,765,292)
Other income (expense) [1] 24,117
Unrealized loss on digital assets holdings (22,010,362)
Consolidated total loss before income taxes (24,751,537)
Clinical Stage Bio Technology [Member]    
Segment Reporting Information [Line Items]    
Total assets 5,181,535 3,721,624
Loss from operations (17,340,774) (12,433,792)
Other income (expense) [1] (11,052) 236,224
Consolidated total loss before income taxes $ (17,351,826) $ (12,197,568)
[1] Other income (expense) consists of interest income and interest expense.